ECSP21072036A - Composición farmacéutica que contiene acetaminofeno e ibuprofeno - Google Patents

Composición farmacéutica que contiene acetaminofeno e ibuprofeno

Info

Publication number
ECSP21072036A
ECSP21072036A ECSENADI202172036A ECDI202172036A ECSP21072036A EC SP21072036 A ECSP21072036 A EC SP21072036A EC SENADI202172036 A ECSENADI202172036 A EC SENADI202172036A EC DI202172036 A ECDI202172036 A EC DI202172036A EC SP21072036 A ECSP21072036 A EC SP21072036A
Authority
EC
Ecuador
Prior art keywords
ibuprofen
pharmaceutical composition
composition containing
containing acetaminophen
acetaminophen
Prior art date
Application number
ECSENADI202172036A
Other languages
English (en)
Inventor
Maura Murphy
Matt Callahan
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of ECSP21072036A publication Critical patent/ECSP21072036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas farmacéuticas orales sólidas que contienen 325 mg de acetaminofeno y 97,5 mg de ibuprofeno o 500 mg de acetaminofeno y 150 mg de ibuprofeno, en donde el ibuprofeno tiene un [D50] entre 1 y 9 μm.
ECSENADI202172036A 2019-02-27 2021-09-27 Composición farmacéutica que contiene acetaminofeno e ibuprofeno ECSP21072036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/287,836 US11197830B2 (en) 2019-02-27 2019-02-27 Pharmaceutical composition containing acetaminophen and ibuprofen
PCT/US2020/020112 WO2020176736A1 (en) 2019-02-27 2020-02-27 Pharmaceutical composition containing acetominophen and ibuprofen

Publications (1)

Publication Number Publication Date
ECSP21072036A true ECSP21072036A (es) 2021-11-30

Family

ID=72140141

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202172036A ECSP21072036A (es) 2019-02-27 2021-09-27 Composición farmacéutica que contiene acetaminofeno e ibuprofeno

Country Status (23)

Country Link
US (4) US11197830B2 (es)
EP (1) EP3930691A4 (es)
CN (1) CN113795243A (es)
AU (4) AU2019268077B2 (es)
BR (1) BR112021017037A2 (es)
CA (1) CA3131917A1 (es)
CL (1) CL2021002252A1 (es)
CO (1) CO2021011525A2 (es)
CR (1) CR20210451A (es)
EA (1) EA202192118A1 (es)
EC (1) ECSP21072036A (es)
GB (1) GB2595406B (es)
IL (1) IL285866A (es)
JO (1) JOP20210235A1 (es)
MA (2) MA62176A1 (es)
MX (1) MX2021010338A (es)
NZ (1) NZ759337A (es)
PE (1) PE20220591A1 (es)
SG (1) SG11202109258WA (es)
TN (1) TN2021000176A1 (es)
TW (1) TW202045148A (es)
UA (1) UA127775C2 (es)
WO (1) WO2020176736A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
AU2020301401B2 (en) * 2019-06-27 2023-12-21 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Novel ibuprofen and acetaminophen composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5148139B2 (es) 1972-09-30 1976-12-18
AU605538B2 (en) 1988-01-19 1991-01-17 Adcock Ingram Limited Pharmaceutical unit
CA1336687C (en) 1989-08-23 1995-08-15 Thomas M. Tencza Process for preparing tablets containing ibuprofen, apap and caffeine, the products of this process and the use of such products
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5260337A (en) 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
JP3982889B2 (ja) 1997-11-28 2007-09-26 あすか製薬株式会社 イブプロフェン含有医薬製剤
US6440983B1 (en) 2000-12-21 2002-08-27 Mary Theresa Frank-Kollman Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
GB0414442D0 (en) 2004-06-28 2004-07-28 Borealis As Zeolite catalysts
US20080275125A1 (en) * 2004-07-07 2008-11-06 Aft Pharmaceuticals Limited Combination Composition
KR20060072839A (ko) 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
GB0519350D0 (en) 2005-09-22 2005-11-02 Boots Healthcare Int Ltd Therapeutic agents
WO2008079818A2 (en) 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
JP5148139B2 (ja) 2007-03-12 2013-02-20 パナソニック株式会社 半導体装置及びその製造方法
WO2009012590A1 (en) * 2007-07-23 2009-01-29 Kingsway Pharmaceuticals Inc. Therapeutic formulations for the treatment of cold and flu-like symptoms
US20090264530A1 (en) 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
PL2341900T3 (pl) 2008-10-14 2019-08-30 Aft Pharmaceuticals Limited Produkt medyczny i leczenie
DK2421513T3 (en) 2009-04-24 2018-03-26 Iceutica Pty Ltd UNKNOWN FORMULATION WITH INDOMETHACIN
SG175308A1 (en) 2009-04-24 2011-11-28 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
US11135188B2 (en) * 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
MY164112A (en) 2010-07-07 2017-11-30 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
CL2010000738A1 (es) 2010-07-08 2011-03-25 Wockhardt Res Centre Suspension farmaceutica oral que comprende desde 100 hasta 500 mg/5ml de paracetamol, desde 40 hasta 80 mg/5ml de ibuprofeno o desde 200 hasta 400 mg/5ml de paracetamol, desde 100 hasta 200 mg/5ml de ibuprofeno y uno o mas excipientes farmaceuticamente aceptables, util para tratar el dolor pre, peri o postoperatorio.
MX2013005113A (es) * 2010-11-04 2013-06-03 Aft Pharmaceuticals Ltd Una composicion combinada.
JP5830412B2 (ja) 2011-03-02 2015-12-09 ライオン株式会社 水難溶性薬物と賦形剤との粉砕物の製造方法、造粒粒子の製造方法、錠剤の製造方法
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen

Also Published As

Publication number Publication date
AU2019268077B2 (en) 2021-02-25
UA127775C2 (uk) 2023-12-27
AU2024203208A1 (en) 2024-05-30
EP3930691A1 (en) 2022-01-05
CR20210451A (es) 2021-12-02
BR112021017037A2 (pt) 2021-11-09
PE20220591A1 (es) 2022-04-22
GB202112205D0 (en) 2021-10-13
GB2595406A (en) 2021-11-24
TW202045148A (zh) 2020-12-16
CL2021002252A1 (es) 2022-04-29
AU2021200634A1 (en) 2021-03-04
CN113795243A (zh) 2021-12-14
CA3131917A1 (en) 2020-09-03
CO2021011525A2 (es) 2021-09-20
TN2021000176A1 (en) 2023-04-04
IL285866A (en) 2021-10-31
MX2021010338A (es) 2022-01-07
US20200268673A1 (en) 2020-08-27
AU2022201196A1 (en) 2022-03-17
AU2019268077A1 (en) 2020-09-10
WO2020176736A1 (en) 2020-09-03
SG11202109258WA (en) 2021-09-29
AU2021200634B2 (en) 2022-03-10
EA202192118A1 (ru) 2021-11-18
EP3930691A4 (en) 2022-11-30
US11534407B2 (en) 2022-12-27
US11197830B2 (en) 2021-12-14
US20220175680A1 (en) 2022-06-09
JOP20210235A1 (ar) 2023-01-30
MA54028B2 (fr) 2023-10-31
MA62176A1 (fr) 2024-01-31
US11872317B2 (en) 2024-01-16
GB2595406B (en) 2023-05-10
US20230201125A1 (en) 2023-06-29
US20240091160A1 (en) 2024-03-21
MA54028A1 (fr) 2022-06-30
NZ759337A (en) 2023-06-30

Similar Documents

Publication Publication Date Title
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
ECSP21072036A (es) Composición farmacéutica que contiene acetaminofeno e ibuprofeno
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
CL2017003320A1 (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
PA8809601A1 (es) Combinación anti-retroviral
CL2020001358A1 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
EP4011375A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE, ORAL TABLET BASED ON NITROXOLINE, METHOD FOR PREPARATION AND USE
TR201913472A2 (tr) Vi̇ldagli̇pti̇n ve metformi̇n i̇çeren bi̇r kombi̇nasyon
TR201914406A2 (tr) Sapropteri̇n di̇hi̇droklorür ve en az bi̇r farmasöti̇k eksi̇pi̇yan i̇çeren kati oral farmasöti̇k formülasyonlar
CY1125762T1 (el) Νεα απο του στοματος σκευασματα βελινοστατης
EP3765072A4 (en) 3,5-DIALCOXYBENZOYL-3'-AMINO-3'-DEOXYADENOSINE-5'-TRIPHOSPHATE AND THEIR PHARMACEUTICAL USES THEREOF
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
AU2017256125A1 (en) Oral composition
TR201818986A2 (tr) İvabradi̇n ve metoprolol i̇çeren kati oral farmasöti̇k kompozi̇syonlar
TR2023017232A2 (tr) 5 mg ve 10 mg melatoni̇n i̇çeren farmasöti̇k formülasyonlar
NI201900084A (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
CL2022000990A1 (es) Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1
CO2021012300A2 (es) Composición del cuidado oral
MX2020004546A (es) Composiciones farmaceuticas orales de lorazepam resistentes al alcohol.
EA201990506A1 (ru) Фармацевтическая композиция